Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 8/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495216 | 0.92 | KDM4E (0.41) | MAPK1ALDH1A1KDM4EKDR | |
| SCHEMBL1507501 | 0.85 | PDE3B (0.43) | EGFRMAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL30820428 | 0.84 | ALDH1A1 (0.37) | MAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL4377096 | 0.83 | KDM4E (0.38) | MAPK1ALDH1A1KDM4E | |
| SCHEMBL4376396 | 0.83 | PDE3B (0.40) | MAPK1ALDH1A1KDM4E | |
| SCHEMBL3329620 | 0.83 | PDE3B (0.40) | MAPK1ALDH1A1KDM4E | |
| SCHEMBL1507437 | 0.83 | ALDH1A1 (0.43) | MAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL2002754 | 0.82 | KDM4E (0.46) | MAPK1ALDH1A1KDM4EKDR | |
| SCHEMBL4375766 | 0.82 | PDE3B (0.39) | MAPK1ALDH1A1KDM4E | |
| SCHEMBL4297391 | 0.82 | PRKAB2 (0.42) | MAPK1ALDH1A1KDM4EKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133999-B2 | Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one | UBE INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | claimed |
| EP-1650196-B1 | PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE | UBE INDUSTRIES (JP) | 2011-03-30 | — | — | EP | claimed |
| US-20090253909-A1 | PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE | UBE INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | claimed |
| US-20060276647-A1 | Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one | UBE INDUSTRIES, LTD (JP) | 2006-12-07 | — | — | US | claimed |
| EP-1650196-A1 | PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE | Ube Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | claimed |
| CN-104910080-A | Novel erlotinib-related substance and preparation method thereof | UNIV DALIAN TECH | 2015-09-16 | — | — | CN | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8133999-B2 | Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one | UBE INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133999-B2 | Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one | UBE INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133999-B2 | Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one | UBE INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-2307386-A1 | CRYSTALLINE FORMS OF ERLOTINIB BASE AND ERLOTINIB HCL | PLUS CHEMICALS S.A. (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20040259881-A1 | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO CO, LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
| EP-1309567-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016360-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276647-A1 | Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one | CPS1, CYP3A4, RPS27A | EGFR 3857/4885MAPK1 2412/4885ALDH1A1 1913/4885 |
| US-20040259881-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, PDGFRA | EGFR 32/4885MAPK1 258/4885ALDH1A1 3597/4885 |
| US-20090253909-A1 | PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE | CYP4F11, OGFR, CYP4B1 | EGFR 248/4885MAPK1 584/4885ALDH1A1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.